This paper evaluates the pro-arrhythmia risk and inotropic effects of Hydroxychloroquine, Chloroquine and Azithromycin in the cardiomyocyte contractility-based model of the human heart due to their proposed repurposed use to treat COVID-19. The study conclusion has the potential to inform clinical studies evaluating repurposed therapies and demonstrates the translational value of human cardiomyocyte contractility-based model for novel COVID-19 therapies.

PUBLICATION: Society of Toxicology (2021)

AUTHORS: Pierre Jordaan, Berenge`re Dumotier, Martin Traebert, Paul E. Miller, Andre Ghetti, Laszlo Urban and Najah Abi-Gerges